MT-TL1 and glioma: The methyltransferase RNMT/RAMAC complex is required for efficient RNA capping, catalyzing the methylation of the guanosine cap at the N7 position, converting it into 7-methylguanosine (m7G) – a crucial modification in RNA polymerase II-transcribed RNA.99 Another m7G modification regulator, MTTL1, has been associated with drug resistance in various cancers and is found to be upregulated in gliomas.100 Although the precise role of the RNMT/RAMAC complex remains unclear, based on previous reports, its downregulation may be a beneficial outcome in the context of glioma treatment response.